

How to submit prior authorization requests for medical benefit drugs

For Blue Cross commercial and BCN commercial

Revised May 2025

Follow these steps to submit prior authorization requests when prescribing most drugs covered under the medical benefit for Blue Cross Blue Shield of Michigan and Blue Care Network commercial members.

Note: The information below doesn't apply to oncology medical benefit drugs.

Michigan prescribers

To submit prior authorization requests electronically:

1. Log in to our provider portal (availability.com*).
2. Click *Payer Spaces* on the menu bar and click the BCBSM and BCN logo.
3. Click the *Medical/Pharm Drug Benefit Prior Auth (Commercial)* tile on the Applications tab.
4. In the Medical and Pharmacy Drug PA Portal, click the *Authorization* menu and select *Add New*.
5. Enter the member's last name, date of birth, subscriber ID and authorization start date.
6. Click *Search* and then select the appropriate member in the member list.
7. Complete all required fields and submit the request.

If you're registered for Availity Essentials™ but aren't able to access it, submit the prior authorization request using the *Medication Authorization Request Form*, or *MARF*, that's on the next page. Fax it to the number on the form.

Non-Michigan prescribers

When submitting prior authorization requests, prescribers located outside of Michigan should complete the appropriate steps on the [Getting Started](#) page on ereferrals.bcbsm.com. Look in the *Submit prior authorization requests* section.

If a non-Michigan prescriber is unable to submit a prior authorization request using the instructions on the webpage, submit the request using the *Medication Authorization Request Form*, or *MARF*, that's on the next page. Fax it to the number on the form.

Information about the Medical and Pharmacy Drug PA Portal

To help you learn how to use the Medical and Pharmacy Drug PA Portal, view a recorded demo by going to Blue Cross and BCN's Provider Training site, searching on *drugs* and launching the *Medical and Pharmacy Drug PA Portal Overview*.

For detailed information about accessing the Provider Training site, see the "Online training" section of the [Training Tools](#) page on ereferrals.bcbsm.com.

*Clicking this link means that you're leaving the Blue Cross Blue Shield of Michigan and Blue Care Network website. While we recommend this site, we're not responsible for its content.

Availity® is an independent company that contracts with Blue Cross Blue Shield of Michigan and Blue Care Network to offer provider portal and electronic data interchange services.

Blue Cross Blue Shield/Blue Care Network of Michigan

Medication Authorization Request Form

Remicade® (infliximab) J1745, infliximab J1745, Inflectra™ (infliximab-dyyb) Q5103, Renflexis™ (infliximab-abda) Q5104, Avsola™ (infliximab-axxq) Q5121



This form is to be used by participating physicians to obtain coverage for Remicade, Inflectra, Renflexis, and Avsola. For commercial members only, please complete this form and submit via fax to 1-877-325-5979. If you have any questions regarding this process, please contact BCBSM Provider Relations and Servicing or the Medical Drug Helpdesk at 1-800-437-3803 for assistance.

PATIENT INFORMATION

PHYSICIAN INFORMATION

Name

Name

ID Number

Specialty

D.O.B.

☐ Male ☐ Female

Address

Diagnosis

City /State/Zip

Drug Name

Phone/Fax: P: () - F: () -

Dose and Quantity

NPI

Directions

Contact Person

Date of Service(s)

Contact Person Phone
/ Ext.

STEP 1: DISEASE STATE INFORMATION

- Initiation or Continuation of therapy? ☐ Initiation ☐ Continuation *Date patient started therapy: _____*
- Site of administration? ☐ Provider office/Home infusion ☐ Other: _____
☐ Hospital outpatient facility (go to #3) *Reason for Hospital Outpatient administration: _____*
- Please specify location of administration if hospital outpatient infusion: _____**
- Please provide the NPI number for the place of administration: _____**
- What is the Patient's weight in Kg? _____ Date recorded: _____
- Primary Indication: ☐ Crohn's Disease (**See #7b**) ☐ Ulcerative Colitis (**See #7b**) ☐ Rheumatoid Arthritis (**See #7c**)
☐ Psoriatic Arthritis ☐ Plaque psoriasis (**See #7d**) ☐ Ankylosing spondylitis
☐ Generalized pustular psoriasis as defined by the European Rare and Severe Psoriasis Expert Network
☐ Other: _____
- Initiation AND Continuation of therapy:**
 - Will the patient be receiving Remicade/Inflectra/Renflexis/Avsola with other biologic agents (for example: Humira, Kineret, Entyvio, or Tremfya, etc.) or with targeted DMARD medications (for example: Otezla)? ☐ Yes ☐ No, Comment: _____
 - Crohn's Disease AND Ulcerative colitis**
 - Does the patient have Crohn's disease with fistula? ☐ Yes ☐ No
 - Which therapies has the patient tried and failed?
☐ Systemic corticosteroids (e.g. 40 to 60 mg prednisone, prednisolone) daily for 7 days
☐ Immunomodulatory therapy for at least 2 months (e.g. azathioprine, mercaptopurine, or methotrexate)
☐ None ☐ Other: _____
 - Rheumatoid Arthritis (RA):**
 - Has the patient had documented failure of at least 3 months of an oral DMARD? (e.g. hydroxychloroquine, methotrexate, leflunomide, or sulfasalazine)
☐ Yes, Length of therapy: _____ ☐ No
 - Will the patient be taking infliximab in combination with methotrexate? ☐ Yes ☐ No, Provide rationale: _____
 - Plaque Psoriasis:**
 - Has the patient experienced treatment failure with one topical corticosteroid?
☐ Yes, Please list topical corticosteroids the patient has tried: _____
☐ No, Comment: _____
- Which medication has the patient tried and failed at optimized dose? ☐ Inflectra ☐ Avsola ☐ Other: _____
 - What was the maximum dose the patient received of Inflectra in mg/kg and frequency? _____
 - What was the maximum dose the patient received of Avsola in mg/kg and frequency? _____
 - How has the patient failed Inflectra and Avsola therapy?
☐ Hypersensitivity reaction (for example: hives during infusion), Please specify: _____
☐ Side effects, Please specify: _____
☐ Lack of efficacy (for example: abdominal pain, bloody stools, etc.), Please specify: _____
☐ Other, Please specify: _____
- Continuation Request:** Remicade/Inflectra/Renflexis/Avsola Start Date _____
 - Has the patient's signs and symptoms improved with Remicade/Inflectra/Renflexis/Avsola? ☐ Yes ☐ No Comment: _____

Please add any other supporting medical information necessary for our review

Coverage will not be provided if the prescribing physician's signature and date are not reflected on this document.

☐ Request for expedited review: I certify that applying the standard review time frame may seriously jeopardize the life or health of the member or the member's ability to regain maximum function

Physician's Name	Physician Signature	Date
Step 2: Checklist	☐ Form Completely Filled Out	☐ Attached Chart Notes
Step 3: Submit	By Fax: BCBSM Specialty Pharmacy Mailbox 1-877-325-5979	By Mail: BCBSM Specialty Pharmacy Program P.O. Box 312320, Detroit, MI 48231-2320

Confidentiality notice: This transmission contains confidential information belonging to the sender that is legally privileged. This information is intended only for use of the individual or entity named above. The authorized recipient of this information is prohibited from disclosing this information to any other party. If you are not the intended recipient, you are hereby notified that any disclosure, copying, distribution or action taken in reliance on the contents of this document is strictly prohibited. If you have received this in error, please notify the sender to arrange for the return of this document.

1/31/2020; 7/1/2020; 2/4/2021; 12/9/2021; 10/7/2022